Beschreibung

Inflammatory and proteolytic activity markers in the IBS model show that Bifidobacterium breve CNCM I-5644 supplementation is associated with reduced intestinal inflammation and decreased serine protease activity compared to untreated controls.

Figure 2

Chart

Source Paper

Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome.

Scientific reports (2022)

PMID: 36396717

DOI: 10.1038/s41598-022-21746-8

Cite This Figure

![Figure 2: Inflammatory and proteolytic activity markers in the IBS model show that Bifidobacterium breve CNCM I-5644 supplementation is associated with reduced intestinal inflammation and decreased serine protease activity compared to untreated controls.]()

> Source: Edgar Torres-Maravilla et al. "Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeabili." *Scientific reports*, 2022. PMID: [36396717](https://pubmed.ncbi.nlm.nih.gov/36396717/)

<figure>
  <img src="" alt="Inflammatory and proteolytic activity markers in the IBS model show that Bifidobacterium breve CNCM I-5644 supplementation is associated with reduced intestinal inflammation and decreased serine protease activity compared to untreated controls." />
  <figcaption>Figure 2. Inflammatory and proteolytic activity markers in the IBS model show that Bifidobacterium breve CNCM I-5644 supplementation is associated with reduced intestinal inflammation and decreased serine protease activity compared to untreated controls.<br>  Source: Edgar Torres-Maravilla et al. "Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeabili." <em>Scientific reports</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36396717/">36396717</a></figcaption>
</figure>

Beschreibung

Figure 2

Source Paper

Cite This Figure

Verwandte Evidenz